LCAR-B4822M-02 Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma
Status:
Unknown status
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
This is a single arm, open-label, phase 1 study, to determine the safety and efficacy of
LCAR-B4822M CAR-T cells in treating patients diagnosed with refractory/relapsed multiple
myeloma (r/r MM).
Phase:
Phase 1
Details
Lead Sponsor:
Second Affiliated Hospital of Xi'an Jiaotong University